{name}
{subtitle}
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
city
~21 mi. (Medford, Wisconsin, +523 more cities)
facility
Aspirus Medford Hospital
drug
cabozantinib, +2 more drugs
drug type
immunotherapy, +1 more type
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
city
~21 mi. (Medford, Wisconsin, +825 more cities)
facility
Aspirus Medford Hospital
biomarker
AKT1 Mutation, +91 more biomarkers
condition
Breast Carcinoma, +3 more conditions
drug
adavosertib, +26 more drugs
drug type
immunotherapy, +1 more type
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
city
~21 mi. (Medford, Wisconsin, +469 more cities)
facility
Aspirus Medford Hospital
drug
carboplatin, +6 more drugs
drug type
chemotherapy, +2 more types
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
city
~21 mi. (Medford, Wisconsin, +556 more cities)
facility
Aspirus Medford Hospital
biomarker
CD19 Expression, +2 more biomarkers
drug
ibrutinib, +2 more drugs
drug type
chemotherapy, +2 more types